No Prescription |
 |
 | ||
|
VERTIN Serc |
|
| ||
No Prescription » Prescription Drugs 17 » VERTIN Serc Betahistine which is a medicine that closely resembles the natural substance histamine. (NB. Betahistine is also available without a brand name ie as the generic medicine.) Betahistine is used to relieve the symptoms of MÚniÞre's disease which is a disorder of the inner ear. The fluid in the ear (found in a structure called the labyrinth) provides continual feedback to the brain about our body position. When something disturbs the balance of this fluid for example an increase in its pressure this can cause sensations such as nausea dizziness or spinning sensations (vertigo) ringing in the ears (tinnitus) and hearing problems. This is what happens in MÚniÞre's disease. Buy VERTIN Serc and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About VERTIN Serc: Product Type: Prescription Drugs 17 VERTIN ( Serc Generic Betahistine ) VERTIN (Serc Generic Betahistine) Serc Generic Betahistine 16mg Tabs Serc Generic Betahistine VERTIN
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
